lead plaintiff deadline

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.

Mereo BioPharma faces securities lawsuit alleging misrepresentations about Phase 3 trial results for setrusumab, causing investor losses.

REGENXBIO faces securities lawsuit alleging misleading statements about RGX-111 gene therapy. Lead plaintiff deadline extended to April 14, 2026.

Law firm announces March 9, 2026 deadline for shareholders to seek lead plaintiff status in securities class actions against Ardent Health and Varonis Systems over alleged misstatements.

Navan IPO investors with losses over $100,000 have until April 24, 2026 to file for lead plaintiff status in a class action alleging the company concealed marketing expense increases before going public.

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.

BellRing Brands faces securities lawsuit alleging material non-disclosure from November 2024 to August 2025. Stock fell 52% after two guidance cuts amid retail inventory reductions and competition.

uniQure faces class action lawsuit over failing to disclose FDA rejection of AMT-130 drug candidate, causing 49% stock decline. Lead plaintiff deadline: April 13, 2026.

Enphase Energy faces securities class action for alleged disclosure failures. Lead plaintiff deadline is April 20, 2026 for investors with losses exceeding $100,000.

CoreWeave faces securities class action for allegedly omitting material disclosures about operational risks and supply chain vulnerabilities. Investors with losses over $100K must apply by March 13, 2026.

Securities class action filed against Ardent Health after November 2025 disclosure of $43M revenue decrease and undisclosed liability reserves. Stock fell 34%; lead plaintiff applications due March 9, 2026.

Four companies face securities fraud class action lawsuits for allegedly making false statements. Investors have until late March 2026 to nominate lead plaintiffs.

BellRing Brands faces class action lawsuit alleging it misrepresented sales performance by failing to disclose that revenue growth was driven by customer inventory buildup rather than organic demand.

Ardent Health faces class action lawsuit over inflated receivables and delayed loss recognition. Stock dropped 34% after $43M revenue restatement; investors have until March 9 to join.

Agilon Health faces class action lawsuit over false 2025 financial guidance. Lead plaintiff deadline set for March 2, 2026; eligible investors urged to apply.

Rosen Law Firm sues Richtech Robotics for allegedly making false Microsoft partnership claims. Class action targets investors who bought stock January 27-29, 2026.

NuScale Power faces securities fraud lawsuit over alleged misrepresentations about its ENTRA1 Energy partnership. Stock fell 70% after November 2025 disclosures of $495M payment and $532M loss.

Vistagen Therapeutics shareholders must file for lead plaintiff status by March 16, 2026 in securities fraud lawsuit alleging false statements and undisclosed risks.

Class action investigations launched against Ramaco Resources and Beyond Meat for alleged securities violations. Investors face deadlines of March 31 and March 24, 2026, respectively, to petition as lead plaintiffs.

Varonis Systems faces securities lawsuit alleging false statements about revenue projections during SaaS transition. Investor deadline for lead plaintiff status is March 9, 2026.